The company closed the sale of 6 series of Notes maturing in 2026, 2030, 2031, 2035, 2055 and 2064 on October 31, 2024, with coupons ranging from 4.500% to 5.850%.

8-KOther EventsFiled Oct 31, 2024Period of report Oct 22, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company closed the sale of 6 series of Notes maturing in 2026, 2030, 2031, 2035, 2055 and 2064 on October 31, 2024, with coupons ranging from 4.500% to 5.850%.
Elevance Health sold the 2026 Notes at $350 million, the 2030 Notes at $750 million, the 2031 Notes at $750 million, the 2035 Notes at $1,200 million, the 2055 Notes at $1,350 million and the 2064 Notes at $800 million, and received proceeds of about $5,138.3 million after deducting underwriting discounts and issuance costs.
The company said it plans to use the net proceeds for working capital and general corporate purposes, including but not limited to funding acquisitions, repaying short-term and long-term debt, and repurchasing common stock under its share repurchase program.
The company said the 2026 Notes mature on October 30, 2026 and the 2064 Notes mature on November 1, 2064. Interest on the 2026 Notes is payable semi-annually in arrears on April 30 and October 30 each year, beginning on April 30, 2025.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Elevance Health closes 6 series of Notes on October 31, 2024

The company closed the sale of 6 series of Notes maturing in 2026, 2030, 2031, 2035, 2055 and 2064 on October 31, 2024, with coupons ranging from 4.500% to 5.850%.

Source · Based on the filing body and exhibits

Principal by series and about $5,138.3 million in proceeds

Elevance Health sold the 2026 Notes at $350 million, the 2030 Notes at $750 million, the 2031 Notes at $750 million, the 2035 Notes at $1,200 million, the 2055 Notes at $1,350 million and the 2064 Notes at $800 million, and received proceeds of about $5,138.3 million after deducting underwriting discounts and issuance costs.

Source · Based on the filing body and exhibits

Use of net proceeds

The company said it plans to use the net proceeds for working capital and general corporate purposes, including but not limited to funding acquisitions, repaying short-term and long-term debt, and repurchasing common stock under its share repurchase program.

Source · Based on the filing body and exhibits

Maturity dates and interest payment schedule

The company said the 2026 Notes mature on October 30, 2026 and the 2064 Notes mature on November 1, 2064. Interest on the 2026 Notes is payable semi-annually in arrears on April 30 and October 30 each year, beginning on April 30, 2025.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.